A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol
Open Access
- 12 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pediatrics
- Vol. 20 (1), 1-9
- https://doi.org/10.1186/s12887-020-02061-5
Abstract
Few clinical trials have been reported for patients with intermediate-risk neuroblastoma because of the scarcity of the disease and the variety of clinical and biological characteristics. A multidisciplinary treatment that consists of multidrug chemotherapy and surgery is expected to lead to a good prognosis with few complications. Therefore, a clinical trial for patients with intermediate-risk tumors was designed to establish a standard treatment that reduces complications and achieves good outcomes. We planned a prospective phase 2, single-arm study of the efficacy of image-defined risk factors (IDRF)-based surgical decision and stepwise treatment intensification for patients with intermediate-risk neuroblastomas. For the localized tumor group, IDRF evaluations will be performed after each three-course chemotherapy, and surgery will be performed when appropriate. For patients with metastatic tumors, a total of five chemotherapy courses will be performed, and primary lesions will be removed when the IDRF becomes negative. The primary endpoint is 3-year progression-free survival rate, and the secondary endpoints include 3-year progression-free survival rates and overall survival rates of the localized group and the metastasis group and the incidence of adverse events. From international results, 75% is considered an appropriate 3-year progression-free survival rate. If this trial’s expected 3-year progression-free survival rate of 85% is statistically greater than 75% in the lower limit of the 95.3% confidence interval, with an accuracy 10% (85 ± 10%), both groups require more than 65 patients. This study is the first clinical trial on the efficacy of IDRF-based surgical decision and stepwise treatment intensification for patients with intermediate-risk neuroblastomas. We expect that this study will contribute to the establishment of a standard treatment for patients with intermediate-risk neuroblastoma. UMIN000004700, jRCTs051180203; Registered on December 9, 2010.Keywords
This publication has 16 references indexed in Scilit:
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Surgical Risk Factors in Primary Surgery for Localized Neuroblastoma: The LNESG1 Study of the European International Society of Pediatric Oncology Neuroblastoma GroupJournal of Clinical Oncology, 2005
- Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factorsAnnals of Oncology, 2002
- Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992European Journal of Cancer, 2000
- Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group StudyJournal of Clinical Oncology, 2000
- Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposideBritish Journal of Cancer, 1998
- Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.Journal of Clinical Oncology, 1998
- Thoracic neuroblastoma: A pediatric oncology group studyJournal of Pediatric Surgery, 1993
- Surgicopathologic staging of neuroblastoma: Prognostic significance of regional lymph node metastasesThe Journal of Pediatrics, 1983
- Factors influencing survival of children with nonmetastatic neuroblastomaCancer, 1976